Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study

HIV Clinical Trial

— HIV-POGO  

Official title:

Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02555930
• Other study ID #: 14/LO/1574
• Status: Completed
• Start date: December 1, 2014
• Est. completion date: January 1, 2019

Study information

• Verified date: March 2021
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to recruit a cohort of HIV patients with and without HIV-SN and to identify genetic risk factors for the development of HIV-SN and neuropathic pain. It also aims to more deeply phenotype the condition, using well validated questionnaires, and to identify any influence that early neurocognitive dysfunction may have on the reporting, diagnosis and treatment of neuropathic pain in the HIV population.

Description:

HIV associated sensory neuropathy (HIV-SN) is a frequent complication of HIV infection, affecting between 20 and 57% of infected individuals. The advent of better antiretroviral treatment for HIV has meant that mortality from HIV has decreased dramatically in the UK. This means however, that chronic, age-related conditions associated with HIV, such as HIV-SN and cognitive impairment, are increasing in prevalence and becoming a significant disease burden.

The classification, diagnosis and treatment of HIV-SN remains poor. Currently, little is known about the genetic basis of the disorder and what risk factors mean that some patients with HIV develop neuropathy and pain, whilst others do not. It is hoped that by further characterising or 'phenotyping' the disorder, it will be easier to identify which patients are at risk of developing neuropathy and chronic pain. It may also mean that treatment can be more individualised as currently patients often undergo a frustrating 'trial and error' protocol of treatment, as clinicians can not yet predict who will respond to which treatment.

It has also been suggested that there is a link between HIV-SN and HIV associated neurocognitive disorder (HAND), which is another common, age-related complication of HIV infection. It may be that the existence of one pathology could predict the development of the other, or that the presence of HAND may impair the diagnosis or treatment of chronic pain associated with HIV-SN.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 148
• Est. completion date: January 1, 2019
• Est. primary completion date: January 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged 18 years or over

• HIV infection

Exclusion Criteria:

• co-incident severe neurological disease

• co-incident severe psychiatric illness

• limited english language skills so as not able to conduct quantitative sensory testing

• pregnancy

• pain of greater than 3/10 on an NRS due to pathology other than HIV-SN

Related Conditions & MeSH terms

• HIV
• Neuralgia
• Neuropathic Pain
• Peripheral Nervous System Diseases
• Sensory Neuropathy

Intervention

Other:
• No Intervention
No intervention - observational only

Locations

Country	Name	City	State
United Kingdom	Pain Research Group, Dept Surgery & Cancer, Imperial College, Chelsea and Westminster Campus	London

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neuropathic Element of Pain Using the Doleur Neuropathique 4 Interview	Doleur Neuropathique 4 Interview score greater than or equal to 4, indicating a high likelihood of neuropathic pain	Day 1
Secondary	Cognitive Function: Global T-score for Cogstate Computerised Cognitive Function Test Set	Cogstate computerised cognitive function testing. A global T-score is a composite measure determined by the arithmetric mean of 8 test scores covering the following cognitive domains: psychomotor function, visual learning, working memory, executive function, emotional recognition, verbal learning, attention and verbal memory. Raw scores were converted to a standardised T score using age adjusted normative data (mean 50; standard deviation 10). Higher scores are interpreted as 'better' cognitive function.	Day 1
Secondary	Conditioned Pain Modulation Efficiency	Conditioned Pain Modulation (CPM) efficiency to protocol using a cold noxious stimulus. The CPM efficiency is calculated as the pressure pain threshold (measured with an algometer on the forearm) during the noxious conditioning stimulus minus the pressure pain threshold prior to conditioning stimulus.	Day 1